UNITY Biotechnology (UBX) Announces CFO Transition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
UNITY Biotechnology Announces CFO Transition
July 6, 2020 5:00 PM EDTSAN FRANCISCO, July 06, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that Bob Goeltz, chief financial officer, will leave the company at the end of July 2020 to pursue a new opportunity. Effective August 1, 2020, Lynne Sullivan, former senior vice president of Biogen, Inc. (Biogen), will become UNITYs interim chief financial officer.
I want to thank Bob for his many contributions and wish him success in his next endeavors, said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. We have a... More
